Celularity Inc. With a focus on off-the-shelf placental-derived allogeneic cell therapies, they offer a range of products and services to target various indications across cancer, immunologic, infectious, and degenerative diseases. Their product portfolio includes genetically modified and unmodified NK cells, engineered T cells (including CAR-T cells), and mesenchymal-like adherent stromal cells (ASCs).

These therapies provide greater expandability, persistence, and stem-ness, enabling them to deliver cutting-edge solutions in cellular medicine. Celularity's mission is to lead the way in cellular medicine by delivering off-the-shelf allogeneic cellular therapies on an unparalleled scale, with top-notch quality and cost effectiveness. They harness the unique biology and ready availability of the placenta to meet the significant unmet global need for allogeneic cellular medicines.

Backed by groundbreaking research, a pioneering technology platform, and a purpose-built manufacturing facility staffed by highly specialized scientists and technicians, Celularity is poised to revolutionize the field of cellular medicine. With their expertise and innovative approach, they are overcoming barriers of scale, quality, and economics to bring life-changing therapies to patients worldwide